August 26, 2024 Press release - Non-regulatory Circio Holding ASA: Invitation to first half-year 2024 presentation on Thursday 29 August at 10:00am CEST
August 12, 2024 Press release - Regulatory Circio Holding ASA – NOK 1.5m requested from Atlas under NOK 10m rights issue commitment
July 26, 2024 Press release - Regulatory Circio Holding ASA – Information about the warrants issued in connection with the rights issue and new share capital registered
July 9, 2024 Press release - Regulatory Circio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue
July 8, 2024 Press release - Regulatory Circio Holding ASA – Last day of the subscription period in the rights issue
July 5, 2024 Press release - Regulatory Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders
July 3, 2024 Press release - Regulatory Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders
July 2, 2024 Press release - Regulatory Circio Holding ASA – Last day of trading in subscription rights in the rights issue
June 28, 2024 Press release - Regulatory Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders
June 26, 2024 Press release - Non-regulatory Circio Holding ASA – Link to online subscription in the rights issue
June 26, 2024 Press release - Regulatory Circio invited to present circVec circular RNA technology at upcoming international RNA therapeutics conferences
June 25, 2024 Press release - Non-regulatory Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
June 24, 2024 Press release - Regulatory Circio Holding ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates
June 24, 2024 Press release - Regulatory Circio Holding ASA – Commencement for the subscription period for the rights issue
June 19, 2024 Press release - Regulatory Circio Holding ASA – Minutes from the annual general meeting 2024 and approval of Rights Issue
June 18, 2024 Press release - Regulatory Circio Holding ASA – Approval and publication of prospectus for the rights issue
June 18, 2024 Press release - Regulatory Circio Holding ASA – Updated key information relating to the rights issue
June 18, 2024 Press release - Regulatory Circio Holding ASA – Updated information to the notice of annual general meeting 2024
June 17, 2024 Press release - Non-regulatory Circio announces strengthened in vivo data and enhanced circVec 2.2 design, presented by management in R&D webcast
June 6, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversions of convertible bonds and change of the ratio of subscription rights in the Rights Issue
June 6, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
June 4, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
June 3, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
May 30, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
May 29, 2024 Press release - Regulatory Circio Holding ASA – Key information relating to the rights issue
May 29, 2024 Press release - Regulatory Circio announces financing that secures cash runway for twelve months
May 29, 2024 Press release - Regulatory Circio Holding ASA – Terms of the rights issue and related transactions
May 13, 2024 Press release - Non-regulatory Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting
April 29, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
April 25, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
April 17, 2024 Press release - Regulatory Circio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus
April 17, 2024 Press release - Regulatory Circio announces intention to raise around NOK 50-60 million in Q2 2024 to extend cash runway to Q2 2025
April 17, 2024 Press release - Regulatory Circio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment
April 9, 2024 Press release - Non-regulatory Circio invites to a company update on Wednesday 17 April 2024
March 27, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
March 21, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
March 19, 2024 Press release - Regulatory Circio announces that partner IOVaxis Therapeutics has exercised the option for an exclusive license to mutant RAS cancer vaccine TG01 in China
March 13, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
March 5, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
March 4, 2024 Press release - Non-regulatory The TG01 IND application by Circio’s partner IOVaxis Therapeutics has been approved by the Chinese regulatory authorities
March 4, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
February 27, 2024 Press release - Non-regulatory Circio to participate in the Annual European Life Sciences CEO Forum in Zürich
February 7, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
February 5, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
February 1, 2024 Press release - Non-regulatory The first patient has been dosed in Circio’s TG01 triple combination study
January 18, 2024 Press release - Regulatory Circio receives waiver of EUR 6.2 million in loans from Business Finland
January 12, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
January 10, 2024 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
January 4, 2024 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
December 28, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
December 22, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
December 19, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
December 18, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
December 13, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
December 12, 2023 Press release - Regulatory TG01 IND application filed in China by Circio’s partner IOVaxis Therapeutics
December 7, 2023 Press release - Regulatory Circio announces completion of planned safety review and opening for full enrollment of TG01 study at Oslo University Hospital
November 30, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
November 29, 2023 Press release - Non-regulatory Reminder: Circio invites to circular RNA R&D webinar today
November 24, 2023 Press release - Non-regulatory Circio announces outcome of TG01/gemcitabine combination EU patent proceeding
November 21, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
November 16, 2023 Press release - Non-regulatory Circio inngår nytt samarbeid i USA for å teste kreftvaksinen TG01 i RAS-mutert kreft
November 16, 2023 Press release - Non-regulatory Circio joins collaboration to test the combination of TG01 vaccination with daratumumab and nivolumab in immunotherapy resistant patients with mutant RAS cancers
November 9, 2023 Press release - Non-regulatory Circio invites to circular RNA R&D webinar Wednesday 29 November 2023
October 26, 2023 Press release - Non-regulatory Circio presents powerful expression data for new generation circVec 2.0 design at the ESGCT 2023 annual meeting
October 19, 2023 Press release - Non-regulatory Circio: circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT)
October 18, 2023 Press release - Regulatory Circio strengthens its focus on next generation circular RNA therapeutics with additional cost reductions
October 10, 2023 Press release - Non-regulatory Circio and Neoregen Biotech enter collaboration for delivery of novel circular RNA therapeutics using NICT technology
October 4, 2023 Press release - Non-regulatory Circio invites to a company update on Wednesday 11 October 2023
October 2, 2023 Press release - Regulatory Circio Holding ASA – Key information relating to the change of ISIN
October 2, 2023 Press release - Regulatory Circio Holding ASA – Key information relating to the reverse share split
September 28, 2023 Press release - Regulatory Circio Holding ASA: Approval and publication of registration document
September 27, 2023 Press release - Regulatory Circio Holding ASA: Minutes from the Extraordinary General Meeting
September 25, 2023 Press release - Non-regulatory Circio: circRNA poster to be presented at the 15th international adenovirus meeting
September 21, 2023 Press release - Regulatory Circio Holding ASA – Technical adjustment to item 7 in the Notice of the Extraordinary General Meeting to be held on 27 September 2023
September 21, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
September 14, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
September 7, 2023 Press release - Non-regulatory Circio invites to Q&A webcast regarding Extraordinary General Meeting
September 6, 2023 Press release - Regulatory Circio Holding ASA – Notice of Extraordinary General Meeting
September 4, 2023 Press release - Non-regulatory ONCOS-102 mesothelioma study published in Journal for ImmunoTherapy of Cancer
August 15, 2023 Press release - Non-regulatory Circio Holding ASA: Invitation to Circio’s first half year 2023 presentation, Thursday 24 August
June 29, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
June 26, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
June 22, 2023 Press release - Non-regulatory Circio: Første pasient med benmargskreft dosert med TG01 i studie på Oslo Universitetssykehus
June 22, 2023 Press release - Non-regulatory Circio: First patient in multiple myeloma trial dosed with TG01 at Oslo University Hospital
June 12, 2023 Press release - Regulatory Circio Holding ASA: Issuance of restricted stock units (RSUs) to the board members
May 31, 2023 Press release - Non-regulatory Circio invites to a company update on Thursday 15 June 2023
May 26, 2023 Press release - Regulatory Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds
May 23, 2023 Press release - Regulatory Circio Holding ASA: Requested Conversion of Convertible Bonds
May 16, 2023 Press release - Non-regulatory Circio: Link to recording and presentation from Company update 16[th] May 2023
May 3, 2023 Press release - Regulatory Targovax ASA – Correction of the proxy form attached to the notice of the Annual General Meeting
May 3, 2023 Press release - Non-regulatory Circio: circRNA poster to be presented at the ASGCT Annual Meeting
April 19, 2023 Press release - Regulatory Targovax skifter navn til Circio og styrker satsingen på sirkulært RNA
April 19, 2023 Press release - Regulatory Targovax to rebrand as Circio, an innovator in next generation circular RNA therapeutics
April 13, 2023 Press release - Non-regulatory Targovax ASA: Registration of share capital increase following conversion of convertible bonds
March 30, 2023 Press release - Non-regulatory Targovax ASA: Requested Conversion of Convertible Bonds
March 15, 2023 Press release - Non-regulatory Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting
March 9, 2023 Press release - Regulatory Targovax ASA: Minutes from the Extraordinary General Meeting
March 7, 2023 Press release - Regulatory Targovax to prioritize resources on unlocking the potential of its circRNA platform
March 6, 2023 Press release - Regulatory Targovax ASA – Additional information prior to the Extraordinary General Meeting
March 6, 2023 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units
March 2, 2023 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs
March 2, 2023 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
March 1, 2023 Press release - Regulatory Targovax ASA – Additional information prior to the Extraordinary General Meeting
February 23, 2023 Press release - Regulatory Targovax invites to Q&A webcast regarding convertible bond financing
February 16, 2023 Press release - Regulatory Targovax annonserer finansiering på inntil 300 millioner til utvikling av kreftmedisin og ny sirkulær RNA plattform
February 16, 2023 Press release - Regulatory Targovax announces financing of up to NOK 300m over three years to advance its clinical cancer programs & pre-clinical circular RNA platform
February 8, 2023 Press release - Regulatory Targovax ASA: Invitation to Targovax’s fourth quarter 2022 presentation, Thursday 16 February
December 22, 2022 Press release - Non-regulatory Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed
December 15, 2022 Press release - Non-regulatory Targovax starter samarbeid med Agenus for å teste TG som behandling mot bukspyttkjertelkreft
December 15, 2022 Press release - Non-regulatory Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer
December 7, 2022 Press release - Non-regulatory Targovax to present and attend at upcoming conferences
November 10, 2022 Press release - Non-regulatory Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
October 26, 2022 Press release - Regulatory Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November
October 20, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info
October 20, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research
October 5, 2022 Press release - Non-regulatory The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting
September 27, 2022 Press release - Non-regulatory Targovax’ studie i føflekkreft har blitt godkjent for oppstart av amerikanske FDA
September 27, 2022 Press release - Non-regulatory Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA
September 26, 2022 Press release - Non-regulatory Reminder: Targovax to host Investor Event 27 September
September 19, 2022 Press release - Non-regulatory Targovax arrangerer investormøte: Møt ledelsen 27. september
September 19, 2022 Press release - Non-regulatory Targovax to host Investor Event: Meet the Management on 27 September
August 18, 2022 Press release - Regulatory Targovax ASA: Second quarter and first half year 2022 results
August 11, 2022 Press release - Non-regulatory Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August
June 23, 2022 Press release - Non-regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA
June 23, 2022 Press release - Non-regulatory Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA
June 23, 2022 Press release - Non-regulatory Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA
June 7, 2022 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units and exercise of employee options
May 31, 2022 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs
May 31, 2022 Press release - Regulatory Targovax ASA: Exercise of options, settlement of restricted stock units and resolutions to increase the share capital
May 27, 2022 Press release - Non-regulatory Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022
May 11, 2022 Press release - Regulatory Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
May 10, 2022 Press release - Non-regulatory Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma
May 3, 2022 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May
April 28, 2022 Press release - Non-regulatory Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO
April 26, 2022 Press release - Non-regulatory Targovax to present at 5th Neoantigen Summit Europe in Amsterdam
April 21, 2022 Press release - Non-regulatory Targovax ASA announces the appointment of two new Board Directors
April 20, 2022 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
March 9, 2022 Press release - Non-regulatory Targovax ASA: Poster presentation at the AACR Annual Meeting
March 8, 2022 Press release - Regulatory Targovax ASA: Registration of share capital increases following exercise of options
March 7, 2022 Press release - Non-regulatory Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
March 2, 2022 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
March 2, 2022 Press release - Regulatory Targovax ASA: Exercise of options under LTI program, settlement of RSUs and resolution to increase the share capital
February 28, 2022 Press release - Regulatory Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer
February 9, 2022 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February
February 1, 2022 Press release - Non-regulatory Targovax inngår forskningssamarbeid med Karolinska Institutet (Norwegian)
February 1, 2022 Press release - Regulatory Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration
January 17, 2022 Press release - Non-regulatory Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan
January 12, 2022 Press release - Regulatory Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
December 22, 2021 Press release - Regulatory Targovax ASA – Registration of share capital increase pertaining to the Rights Issue
December 20, 2021 Press release - Non-regulatory Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
December 15, 2021 Press release - Regulatory Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
December 14, 2021 Press release - Regulatory Targovax ASA – The subscription period for the rights issue expires today
December 13, 2021 Press release - Non-regulatory Targovax to present at DNB’s 12[th] Nordic Healthcare Conference
December 10, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
December 10, 2021 Press release - Regulatory Targovax ASA – Last day of trading in subscription rights
December 10, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
December 1, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
November 30, 2021 Press release - Regulatory Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
November 30, 2021 Press release - Regulatory Targovax ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates
November 30, 2021 Press release - Regulatory Targovax ASA – Commencement of the subscription period for the rights issue
November 29, 2021 Press release - Regulatory Targovax ASA – Approval and publication of the prospectus for the rights issue
November 25, 2021 Press release - Regulatory Targovax ASA – Rights issue approved by the extraordinary general meeting
November 24, 2021 Press release - Regulatory Targovax ASA – Updated key information relating to the preferential rights issue
November 24, 2021 Press release - Regulatory Targovax ASA – Terms of the fully underwritten rights issue
November 18, 2021 Press release - Non-regulatory Targovax invites to webcast presentation in Norwegian
November 9, 2021 Press release - Non-regulatory Targovax announces two posters at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 4, 2021 Press release - Regulatory Targovax ASA – Key information relating to the preferential rights issue
November 4, 2021 Press release - Regulatory Targovax ASA – Notice of extraordinary general meeting – Fully underwritten rights issue
October 27, 2021 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2021 results, Thursday 4 November
October 22, 2021 Press release - Non-regulatory Targovax invites to webcast presentation on Xtrainvestor
October 6, 2021 Press release - Non-regulatory Targovax ASA: Two abstracts accepted at the SITC Congress
September 30, 2021 Press release - Non-regulatory Targovax ASA appoints Ola Melin as Head of Manufacturing
September 24, 2021 Press release - Non-regulatory Targovax granted European Patent for ONCOS-102 in combination with chemotherapy
September 16, 2021 Press release - Non-regulatory Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
August 27, 2021 Press release - Non-regulatory Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress
August 18, 2021 Press release - Regulatory Targovax ASA: second quarter and first half year 2021 results
August 16, 2021 Press release - Non-regulatory Targovax to present at upcoming scientific conferences
August 9, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August
July 9, 2021 Press release - Regulatory Targovax announces resignation of Chief Financial Officer, Torbjørn Furuseth
July 1, 2021 Press release - Regulatory Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
June 28, 2021 Press release - Regulatory Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition
June 22, 2021 Press release - Regulatory Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 17, 2021 Press release - Regulatory Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 14, 2021 Press release - Regulatory Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
June 10, 2021 Press release - Regulatory Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
May 26, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following the settlement of RSUs
May 21, 2021 Press release - Non-regulatory Targovax to present at upcoming investor and scientific conferences
May 19, 2021 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders in connection with settlement of RSUs
May 18, 2021 Press release - Regulatory Targovax ASA: Resolution to increase the share capital following exercise of RSUs
April 27, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s first quarter 2021 results, Thursday 6 May
March 18, 2021 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
March 9, 2021 Press release - Non-regulatory Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors
March 8, 2021 Press release - Non-regulatory Targovax to present and attend at upcoming investor and scientific conferences
March 4, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
March 1, 2021 Press release - Regulatory Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
February 24, 2021 Press release - Non-regulatory Targovax: Proposal for Remuneration Guidelines for Board and Executive Management
February 23, 2021 Press release - Non-regulatory Continued survival benefit in Targovax’s ONCOS-102 trial in mesothelioma at the 21-month follow-up
February 18, 2021 Press release - Non-regulatory Reminder: Invitation to Targovax’s Capital Markets Day 18 February 2021
February 15, 2021 Press release - Non-regulatory Targovax receives Fast-Track designation for ONCOS-102
February 11, 2021 Press release - Non-regulatory Agenda for Targovax’s Capital Markets Day 18 February 2021
February 10, 2021 Press release - Non-regulatory Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
February 9, 2021 Press release - Non-regulatory SOTIO has stopped collaboration trial with the dendritic cell vaccine DCVAC in combination with ONCOS-102
January 11, 2021 Press release - Non-regulatory Targovax to present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 6, 2021 Press release - Non-regulatory Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
December 15, 2020 Press release - Non-regulatory Targovax ASA: Save the date – Capital Markets Day 2021
December 14, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
December 10, 2020 Press release - Non-regulatory Targovax to present at DNB’s 11[th] Annual Nordic Healthcare Conference
December 8, 2020 Press release - Regulatory Targovax ASA: Exercise of options and resolution to increase the share capital
December 2, 2020 Press release - Non-regulatory Targovax ASA: Invitation to online presentation at 10:00 CET 2 December
December 1, 2020 Press release - Non-regulatory Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
November 24, 2020 Press release - Non-regulatory Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
November 17, 2020 Press release - Non-regulatory Targovax to present at Bryan Garnier & Co Virtual European Healthcare Conference
November 9, 2020 Press release - Non-regulatory Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2020 Press release - Non-regulatory Targovax to present at the World Immunotherapy Congress
October 28, 2020 Press release - Non-regulatory Targovax announces formation of new Scientific Advisory Board
October 26, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2020 results, Thursday 5 November
October 22, 2020 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
October 14, 2020 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
October 13, 2020 Press release - Non-regulatory Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
October 12, 2020 Press release - Non-regulatory Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
September 18, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units
September 14, 2020 Press release - Non-regulatory Targovax is invited to present at H.C. Wainwright 22[nd] Annual Global Investment Conference
September 2, 2020 Press release - Non-regulatory Targovax is invited to present at Pareto Nordic Healthcare conference and RAS-targeted drug development summit
August 31, 2020 Press release - Regulatory Targovax ASA: Settlement of restricted stock units by primary insider and resolution to increase the share capital
August 12, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2020 results, Thursday 20 August
June 29, 2020 Press release - Non-regulatory Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
June 24, 2020 Press release - Non-regulatory Targovax announces presentation of pre-clinical data from Next Generation ONCOS at AACR Virtual Annual Conference
June 23, 2020 Press release - Non-regulatory Targovax announces collaboration to evaluate ONCOS-102 in combination with KEYTRUDA® in mesothelioma
June 22, 2020 Press release - Non-regulatory Targovax to present at the upcoming 2020 Virtual European Biotech Investor Day 2020
June 22, 2020 Press release - Non-regulatory Targovax’s ONCOS-102 mesothelioma 12-month data powerfully demonstrate broad immune activation linked to clinical benefit
June 4, 2020 Press release - Non-regulatory Targovax enters collaboration with Leidos to add checkpoint inhibitor functionality to ONCOS viruses
May 14, 2020 Press release - Non-regulatory Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO
May 6, 2020 Press release - Non-regulatory Targovax announces that abstract on interim phase I clinical data from the phase I/II peritoneal trial is accepted at ASCO
May 4, 2020 Press release - Non-regulatory Targovax releases update for mesothelioma trial combining ONCOS-102 and chemotherapy
April 30, 2020 Press release - Non-regulatory Targovax ASA appoints Dr Victor Levitsky as Chief Scientific Officer
April 30, 2020 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 29, 2020 Press release - Non-regulatory Targovax ASA: Invitation to online presentation of Targovax’s first quarter 2020 results, Thursday 7 May
April 22, 2020 Press release - Non-regulatory Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
April 3, 2020 Press release - Non-regulatory Targovax ASA announces proposed new Chairman of the Board
March 30, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units
March 26, 2020 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
March 26, 2020 Press release - Non-regulatory Targovax to present at the 2020 Solebury Trout Virtual Investor Conference today
March 23, 2020 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders in connection with settlement of RSUs
March 20, 2020 Press release - Non-regulatory Impact of corona virus (COVID-19) on Targovax’s operations
March 3, 2020 Press release - Non-regulatory Targovax announces completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma
March 3, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2019 results, Wednesday 11 March
January 28, 2020 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
January 22, 2020 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
January 21, 2020 Press release - Non-regulatory Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy
January 8, 2020 Press release - Non-regulatory Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China
November 11, 2019 Press release - Non-regulatory Presentation of ONCOS-102 melanoma data at SITC Annual Meeting
October 29, 2019 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2019 results, Thursday 7 November
October 9, 2019 Press release - Non-regulatory Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
September 24, 2019 Press release - Non-regulatory Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
August 12, 2019 Press release - Non-regulatory Targovax ASA: Announcement of second quarter and first half results 2019
July 31, 2019 Press release - Non-regulatory Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 15, 2019 Press release - Non-regulatory Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
July 8, 2019 Press release - Regulatory Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
June 18, 2019 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of RSUs
June 13, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider following settlement of RSUs
June 12, 2019 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
June 6, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
June 6, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
June 5, 2019 Press release - Regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
June 3, 2019 Press release - Non-regulatory Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
May 31, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
May 24, 2019 Press release - Regulatory Targovax ASA: Last day of the subscription period in the subsequent offering
May 23, 2019 Press release - Regulatory TARGOVAX ASA – APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS
May 23, 2019 Press release - Regulatory Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 10, 2019 Press release - Regulatory Targovax ASA: Commencement of subscription period in the subsequent offering
May 8, 2019 Press release - Non-regulatory Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
May 2, 2019 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 12, 2019 Press release - Regulatory TARGOVAX ASA – APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS
March 28, 2019 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
March 21, 2019 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
March 19, 2019 Press release - Non-regulatory Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring
March 15, 2019 Press release - Regulatory Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute
March 14, 2019 Press release - Non-regulatory Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
March 8, 2019 Press release - Non-regulatory Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform
February 11, 2019 Press release - Non-regulatory First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma
February 4, 2019 Press release - Non-regulatory Targovax ASA: Announcement of fourth quarter and full year results 2018
January 21, 2019 Press release - Non-regulatory Targovax is invited to present at upcoming investor conferences
January 17, 2019 Press release - Non-regulatory Targovax granted European Patent for mutant-RAS neoantigen platform lead products
December 12, 2018 Press release - Regulatory Targovax Presents at DNB 9th Annual Nordic Healthcare Conference
November 28, 2018 Press release - Non-regulatory Targovax is invited to present at upcoming investor and industry conferences
October 26, 2018 Press release - Regulatory Targovax ASA: Announcement of third quarter 2018 financial results
October 15, 2018 Press release - Non-regulatory Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer
October 12, 2018 Press release - Regulatory Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway
October 11, 2018 Press release - Regulatory Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
October 4, 2018 Press release - Regulatory Targovax to host Capital Markets Day 15 October 2018, in Oslo, Norway
October 1, 2018 Press release - Regulatory Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting
September 27, 2018 Press release - Regulatory Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma
September 27, 2018 Press release - Regulatory Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
September 13, 2018 Press release - Regulatory Targovax strengthens management team with the appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
September 12, 2018 Press release - Regulatory Targovax announces publication of new oncolytic virus data in the Journal of Medical Virology and Cancer Gene Therapy
September 4, 2018 Press release - Regulatory Targovax ASA: Registration of new share capital following settlement of restricted stock units
August 29, 2018 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
August 23, 2018 Press release - Regulatory Targovax ASA: Second quarter and first half year 2018 results
August 15, 2018 Press release - Regulatory Targovax ASA: Invitation to second quarter and first half year 2018 results presentation Thursday 23 August
July 12, 2018 Press release - Regulatory Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC
June 20, 2018 Press release - Regulatory Targovax ASA: Mandatory notification of trade – primary insider
June 19, 2018 Press release - Regulatory Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
June 11, 2018 Press release - Regulatory Targovax strengthens focus on ONCOS oncolytic virus development program
June 4, 2018 Press release - Regulatory Targovax to Present at Jefferies 2018 Global Healthcare Conference
May 24, 2018 Press release - Regulatory Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01
May 16, 2018 Press release - Regulatory Targovax to present at upcoming investor and industry conferences
May 2, 2018 Press release - Regulatory Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
April 25, 2018 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 25, 2018 Press release - Non-regulatory Targovax presentation at ChinaBio Partnering Forum 2018
April 24, 2018 Press release - Regulatory Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May
April 12, 2018 Press release - Regulatory Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
March 24, 2018 Press release - Regulatory Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018
March 1, 2018 Press release - Regulatory Targovax ASA: Issuance of restricted stock unites (RSUs) to the chairman of the board of directors
February 7, 2018 Press release - Regulatory Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
February 6, 2018 Press release - Regulatory Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
January 8, 2018 Press release - Regulatory Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
January 4, 2018 Press release - Regulatory Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
December 18, 2017 Press release - Regulatory Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
December 11, 2017 Press release - Regulatory Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
November 3, 2017 Press release - Regulatory Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
October 27, 2017 Press release - Regulatory Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
October 24, 2017 Press release - Regulatory Targovax ASA: Invitation to third quarter 2017 results presentation Thursday 2 November
October 12, 2017 Press release - Regulatory Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer
October 3, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
September 25, 2017 Press release - Regulatory Targovax granted US Patent for mutant-RAS neoantigen platform lead products
September 12, 2017 Press release - Regulatory Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
September 11, 2017 Press release - Non-regulatory Targovax ASA: Three posters presented at ESMO conference
August 29, 2017 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
August 28, 2017 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
August 25, 2017 Press release - Regulatory Exercise of employee share options and restricted stock units in Targovax ASA
August 23, 2017 Press release - Non-regulatory Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress
August 18, 2017 Press release - Regulatory Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
August 14, 2017 Press release - Regulatory Targovax ASA: Invitation to second quarter and first half 2017 results presentation Thursday 24 August
July 14, 2017 Press release - Regulatory Targovax ASA: Last day of the subscription period in the subsequent offering
July 6, 2017 Press release - Regulatory Targovax ASA: Registration of share capital increase following the private placement
July 3, 2017 Press release - Regulatory Targovax ASA: Commencement of subscription period for the subsequent offering
June 30, 2017 Press release - Regulatory Targovax ASA: Approval and publication of prospectus; the subsequent offering
June 30, 2017 Press release - Regulatory Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
June 26, 2017 Press release - Regulatory Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units
June 22, 2017 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options
June 22, 2017 Press release - Regulatory Targovax ASA: Exercise of employee share options and settlement of restricted stock units in Targovax ASA
June 15, 2017 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of vested restricted stock units
June 14, 2017 Press release - Regulatory Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
June 9, 2017 Press release - Regulatory Targovax ASA – Information on the subsequent offering – Key date information
June 6, 2017 Press release - Regulatory Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
June 6, 2017 Press release - Regulatory Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
May 10, 2017 Press release - Regulatory Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
May 8, 2017 Press release - Regulatory Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
April 28, 2017 Press release - Regulatory Targovax ASA: Issuance of restricted stock unites (RSUs) to the board members
April 20, 2017 Press release - Regulatory Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
April 19, 2017 Press release - Regulatory Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
April 6, 2017 Press release - Regulatory Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
April 4, 2017 Press release - Regulatory Targovax ASA: Proposal from the nomination committee to the annual general meeting 5 April 2017
March 22, 2017 Press release - Regulatory Targovax ASA: The board of directors of Oslo Stock Exchange approves transfer of Targovax ASA to the main list
March 17, 2017 Press release - Regulatory Targovax ASA applies for transfer to Oslo Stock Exchange main list
February 24, 2017 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
February 24, 2017 Press release - Regulatory Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
February 13, 2017 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of restricted stock units
February 10, 2017 Press release - Regulatory Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
February 6, 2017 Press release - Regulatory Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
February 2, 2017 Press release - Regulatory Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
January 5, 2017 Press release - Regulatory Targovax announces appointment of Erik Digman Wiklund as CFO
November 21, 2016 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of employee options
November 21, 2016 Press release - Regulatory Targovax ASA: Exercise of employee share options in Targovax ASA
November 18, 2016 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider
November 10, 2016 Press release - Regulatory Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
November 8, 2016 Press release - Regulatory Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
November 4, 2016 Press release - Regulatory Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
November 2, 2016 Press release - Non-regulatory Targovax announces appointment of Oystein Soug as CEO
October 21, 2016 Press release - Non-regulatory Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
October 17, 2016 Press release - Non-regulatory Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
September 19, 2016 Press release - Non-regulatory Targovax to present at Redeye’s Fight Cancer conference
August 25, 2016 Press release - Regulatory Targovax ASA: Interim Report second quarter and first half year 2016
August 17, 2016 Press release - Non-regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
August 17, 2016 Press release - Non-regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
August 15, 2016 Press release - Regulatory Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August
August 9, 2016 Press release - Non-regulatory Targovax ASA: Allocations to primary insiders in the subsequent offering
August 9, 2016 Press release - Non-regulatory Targovax ASA: Allocations to primary insiders in the subsequent offering
August 8, 2016 Press release - Non-regulatory Targovax ASA – Last day of the subscription period in the subsequent offering
August 8, 2016 Press release - Non-regulatory Targovax ASA – Last day of the subscription period in the subsequent offering
August 4, 2016 Press release - Non-regulatory Targovax ASA – The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET
August 4, 2016 Press release - Non-regulatory Targovax ASA – The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET
July 11, 2016 Press release - Non-regulatory Targovax ASA: Commencement of subscription period for the subsequent offering
July 8, 2016 Press release - Non-regulatory Targovax ASA: Publication of prospectus, listing on Oslo Axess and subsequent offering
July 7, 2016 Press release - Non-regulatory Targovax ASA: Completion of private placement, registration of share capital increase
July 6, 2016 Press release - Non-regulatory Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
July 1, 2016 Press release - Non-regulatory Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
July 1, 2016 Press release - Regulatory Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
June 22, 2016 Press release - Non-regulatory Targovax ASA: Announcement of successful NOK 110 million private placement
June 21, 2016 Press release - Non-regulatory Targovax ASA: Update on bookbuilding for the private placement of NOK 100 – 130 million
June 20, 2016 Press release - Non-regulatory Targovax ASA: Contemplated private placement of NOK 100 – 130 million
June 9, 2016 Press release - Regulatory Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102
June 7, 2016 Press release - Regulatory Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed
June 2, 2016 Press release - Regulatory Targovax receives approval in Australia to conduct a clinical trial with TG02 – an immunotheraphy treatment targeting RAS mutations
May 20, 2016 Press release - Non-regulatory Magnus Jaderberg, CMO of Targovax, has presented at a symposium by The Royal Swedish Academy of Engineering Sciences
May 9, 2016 Press release - Regulatory Targovax to present at BioEquity Europe and its first quarter 2016 results on May 11 – 12, 2016
May 9, 2016 Press release - Non-regulatory Targovax ASA: Registration of share capital increase following exercise of employee options
April 15, 2016 Press release - Non-regulatory Targovax ASA: Grant of restricted stock units to the Board of directors
April 14, 2016 Press release - Regulatory Targovax reports immune response with reduced number of TG01 vaccinations
April 14, 2016 Press release - Non-regulatory Resolution to increase the share capital in Targovax ASA in relation to exercise of employee options
March 15, 2016 Press release - Non-regulatory Targovax to present at forthcoming Life Science and Investor conferences
March 14, 2016 Press release - Regulatory Targovax to present at forthcoming Life Science and Investor conferences
March 10, 2016 Press release - Regulatory Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
February 25, 2016 Press release - Regulatory CORRECTION: Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
February 25, 2016 Press release - Regulatory Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
February 2, 2016 Press release - Regulatory Targovax submits a study of its adenovirus based immune therapy ONCOS-102 to the regulatory authorities in Spain
December 14, 2015 Press release - Non-regulatory DNB’s 6th Annual Health Care Conference, Oslo, 15 December 2015
November 19, 2015 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’ third quarter 2015 results
November 18, 2015 Press release - Regulatory Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS
November 5, 2015 Press release - Regulatory Targovax ASA: Immunotherapy with ONCOS-102 show potential to activate immunologically silent tumors and reduce local immune suppression in advanced tumors
July 2, 2015 Press release - Non-regulatory Targovax AS: Closing of the acquisition of Oncos Therapeutics Oy
June 18, 2015 Press release - Non-regulatory Targovax announces successful NOK 200 million private placement
June 15, 2015 Press release - Non-regulatory Targovax increases size of private placement to NOK 200 million after strong investor demand
June 11, 2015 Press release - Non-regulatory Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology
June 1, 2015 Press release - Non-regulatory Targovax presented safety data and immunological results at the 2015 ASCO Annual Meeting
April 20, 2015 Press release - Non-regulatory Targovax ASA: Oncos Therapeutics presenting at the Anglonordic Life Science Conference on April 23rd in London, UK.
April 13, 2015 Press release - Non-regulatory Targovax has appointed Peter Skorpil as Head of Business Development, effective from April 8th, 2015.
March 9, 2015 Press release - Non-regulatory Targovax has decided to expand the on-going phase I/II clinical study CT-TG01-01 with a new group of up to 13 patients.
February 26, 2015 Press release - Non-regulatory Targovax is pleased to announce Mr. Øystein Soug as the new CFO of the Company from June 1, 2015
February 26, 2015 Press release - Non-regulatory Targovax ASA: Oncos represented at the 8th Annual Life Science CEO Forum & Exhibition March 3rd, 2015 in Zurich, Switzerland
January 26, 2015 Press release - Non-regulatory Targovax ASA: ONCOS-102 Mechanism of Action -video released on the website
January 12, 2015 Press release - Non-regulatory Targovax ASA: ONCOS-102 granted US lung cancer orphan drug designation
January 8, 2015 Press release - Non-regulatory Targovax reports completion of recruitment of patients in the phase I/II clinical trial CT TG01-01
December 17, 2014 Press release - Non-regulatory Targovax ASA: “ONCOS-102 sensitizes tumors to other immunotherapies” – Paper published in the latest issue of OncoImmunology
November 25, 2014 Press release - Non-regulatory Targovax ASA: Oncos Therapeutics receives a positive opinion on orphan drug designation for ONCOS-102
November 20, 2014 Press release - Non-regulatory Targovax ASA: Oncos presented a poster at EORTC-NCI-AACR Meeting 2014
November 10, 2014 Press release - Non-regulatory Targovax ASA: Oncos presented a poster at the SITC Annual Meeting 2014
November 5, 2014 Press release - Non-regulatory Targovax ASA: Sari Pesonen invited to present a poster at EORTC-NCI-AACR 2014, Nov 18-21, in Barcelona
November 5, 2014 Press release - Non-regulatory Targovax ASA: Frans Wuite invited to be a panelist in European Business Angel on Nov 17
November 5, 2014 Press release - Non-regulatory MEET US: DNB Markets Health Care Conference 2014, December 11th 2014, Oslo, Norway
November 3, 2014 Press release - Non-regulatory Targovax AS has reached primary endpoint for the ongoing phase I/II clinical trial CT TG01-01
October 30, 2014 Press release - Non-regulatory Targovax ASA: Frans Wuite presenting Oncos at Bio Europe 2014 on Nov 5, 2014 in Frankfurt
October 27, 2014 Press release - Non-regulatory Targovax ASA: Oncos presenting at the fall seminar of Statisticians in Finnish Pharmaceutical Industry held in Turku, Finland Oct 30, 2014
October 1, 2014 Press release - Non-regulatory Targovax Presentation Arctic Biotech Day September 2014
June 4, 2014 Press release - Non-regulatory Targovax ASA: Oncos Therapeutics recruits Dr Magnus Jaderberg as CMO to strengthen its focus on cancer immunotherapy
June 2, 2014 Press release - Non-regulatory Oncos Therapeutics granted US and EU Orphan Drug Designation for ONCOS-102 in ovarian cancer
May 8, 2014 Press release - Non-regulatory Targovax ASA: ONCOS – achievement in cancer immunotherapy – PRESS RELEASE
February 28, 2014 Press release - Non-regulatory Targovax ASA: ATMP classification for ONCOS-102 by European Medicines Agency
February 6, 2014 Press release - Non-regulatory Targovax TG01 immunotherapy reaches phase IIA in operable pancreatic cancer
January 31, 2014 Press release - Non-regulatory Targovax ASA: Oncos Therapeutics among Top 20 Finnish startup companies by Talouselämä journal
October 15, 2013 Press release - Non-regulatory Oncos Therapeutics nominated the Nordic Star Finland by SwedenBIO
September 15, 2013 Press release - Non-regulatory Professor Hani Gabra joins Clinical Advisory Board of Oncos Therapeutics
July 31, 2013 Press release - Non-regulatory Oncos Therapeutics granted Orphan Drug Designation for CGTG-102 by FDA and EMA
June 21, 2013 Press release - Non-regulatory Oncos Therapeutics nominated again among the most promising startup companies
January 29, 2013 Press release - Non-regulatory First patient included in phase I/II clinical study with TG01 in operable pancreatic cancer
November 14, 2012 Press release - Non-regulatory Oncos Therapeutics appoints experienced industry leader Frans Wuite as President and CEO
May 29, 2012 Press release - Non-regulatory Oncos Therapeutics successfully initiates Phase I clinical study
March 14, 2012 Press release - Non-regulatory Patient recruitment started in C1 study in Finland (in Finnish)
January 25, 2012 Press release - Non-regulatory Secures 13 MNOK for development of pancreas cancer vaccine TG01
